Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

T.P. Hughes, A Hochhaus, H.M. Kantarjian, F. Cervantes, F. Guilhot, D. Niederwieser, P.D. le Coutre, G. Rosti, G.J. Ossenkoppele, C. Lobo, H. Shibayama, X.L. Fan, H.D. Menssen, C. Kemp, R.A. Larson, G. Saglio

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1204-1211
JournalHaematologica
Volume99
Issue number7
DOIs
Publication statusPublished - 2014

Cite this